🇺🇸 FDA
Patent

US 12012463

High affinity monoclonal antibodies targeting glypican-2 and uses thereof

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 12012463 (High affinity monoclonal antibodies targeting glypican-2 and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
45
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/47